Cingulate Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Matthew N. Brams, Chief Medical Officer, had his full-time trial period extended from June 30 to September 30, 2026, maintaining $400,000 annual base salary through that date. At trial end, CEO retains sole discretion to return him to part-time at lower pay. Separately, Cingulate was added to the Russell 3000E Index, expected to increase institutional investor visibility.
Why this rating
CMO trial extension is routine employment admin. Russell inclusion is modest positive for visibility but no material revenue/cash impact relative to $19.4M market cap.
Extracted items
- 5.02 exec change
- 7.01 Reg FD disclosure
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.